Suven Life Sciences announced the grant of one (1) product patent from Canada (2907620) corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases and this Patent is valid through 2033.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
RECOMMENDED FOR YOU